Project description:Profiling of gene expression in Vastus Lateralis from female patients before and after GBP surgery and from lean Control Skeletal muscle samples were obtained from 5 subjects immediately before and 6 months after Gastric Bypass surgery as well as from 6 lean control subjects
Project description:MBD-Seq in Vastus Lateralis from male Subjects before and after GBP surgery Skeletal muscle samples were obtained from subjects immediately before and 6 months after Gastric Bypass surgery
Project description:Cancer cachexia is a multifactorial condition characterized by skeletal muscle loss that impairs longevity and quality of life of the vast majority of cancer patients. However, the ability to develop therapeutic strategies to counter cachexia is impeded by the limited understanding of the underlying mechanisms of cachexia in human cancer patients. The purpose of this study was therefore to characterize the proteomic signature of skeletal muscle obtained from cachectic pancreatic ductal adenocarcinoma (PDAC) patients, who exhibit one of the highest rates of cachexia. Muscle biopsies (rectus abdominis) were obtained from PDAC patients (n=8; 70±10yr; BMI: 26.8±5.9kg･m-2) undergoing tumor resection surgery as well as age and sex-matched non-cancer controls (n=6; 66±9yr; BMI: 30.8±5.2kg･m-2). PDAC patients were cachectic (6 month body weight loss > 5%; mean: 15.7±7.9%) and did not undergo neoadjuvant therapy.
Project description:miRNA profiles were investigated in skeletal muscle in severely obese individuals with or without diabetes before and after Roux-en-Y gastric bypass surgery.
Project description:In the EORTC 90111, open-label, randomised, multicentre, phase II trial, patients were treated with afatinib for 14 days (day 15 until day 1) before surgery (day 0). Tumour biopsies, 2-[fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography (18-FDG PET) and magnetic resonance imaging (MRI) were performed at diagnosis and just before surgery. The main aim of the study was to identify predictive biomarkers among treatment-naive patients in this curative setting.
